UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007571 |
|---|---|
| Receipt number | R000008634 |
| Scientific Title | Gemcitabine and cisplatin combination chemotherapy for patients with unresectable advanced and recurrent biliary tract cancer |
| Date of disclosure of the study information | 2012/03/30 |
| Last modified on | 2012/03/25 22:29:38 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Gemcitabine and cisplatin combination chemotherapy for patients with unresectable advanced and recurrent biliary tract cancer
Acronym
Gemcitabine and cisplatin combination chemotherapy for patients with unresectable advanced and recurrent biliary tract cancer
Scientific Title
Gemcitabine and cisplatin combination chemotherapy for patients with unresectable advanced and recurrent biliary tract cancer
Scientific Title:Acronym
Gemcitabine and cisplatin combination chemotherapy for patients with unresectable advanced and recurrent biliary tract cancer
Region
| Japan |
Condition
Condition
Unresectable and recurrent biliary tract cancer
Classification by specialty
| Hepato-biliary-pancreatic medicine | Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To evaluate the efficacy of gemcitabine / cisplatin combination therapy in patients with unresectable advanced and recurrent biliary tract cancer refractory to gemcitabine and S-1.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Pragmatic
Developmental phase
Phase II
Assessment
Primary outcomes
Response rate
Key secondary outcomes
Time to progression, overall survival, toxicity
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Gemcitabine 1000mg/m2 is administered as 30min intravenous infusion and cisplatin 20mg/m2 is administered as 120min intravenous infusion on day1 and day8. The cycle is repeated every 3 weeks until disease progression.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients with non-resectable or post-operative recurrent biliary tract cancer including intrahepatic cholangiocarcinoma
2) Patients with pathologically proven or graphically confirmed biliary tract cancer
3) Patients with advanced biliary tract cancer refractory to gemcitabine and S-1.
4) Patients with Eastern Chemotherapy Oncology Group(ECOG) performance status of 0-2
5) Patients of age >= 20 years
6) Patients have an adequate organ function defined as white cell count >= 3,000/mm3, platelet count >= 100,000/mm3, hemoglobin >= 9g/dl, total bilirubin <= 3 times the upper limit of normal, AST and ALT <= 5 times the upper limit of normal, creatinine <= 1.5 times the upper limit of normal, and creatinine clearance >= 50ml/min.
7) Written informed consent is required from all patients.
Key exclusion criteria
1) Patients with an active concomitant infection
2) Patients with digestive ulcer or gastrointestinal bleeding
3) Patients with severe cardiovascular or renal disease
4) Patients with an active pulmonary fibrosis or interstitial pneumonia
5) Patients with uncontrollable massive pleural effusion or massive ascites
6) Patients with an active concomitant malignancy
7) Pregnant, lactating female and patients of reproductive potential who did not use effective contraception
8) Patients with a previous history of a severe drug hypersensitivity
9) Patients receiving anti-cancer drugs
10) Inappropriate patients for entry on this study in the judgement of the investigator
Target sample size
50
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Itaru Endo |
Organization
Yokohama City University
Division name
Department of Gastroenterological Surgery
Zip code
Address
3-9, Fukuura, Kanazawa-ku, Kanagawa
TEL
045-787-2650
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name |
Organization
Yokohama City University
Division name
Department of Gastroenterological Surgery
Zip code
Address
3-9, Fukuura, Kanazawa-ku, Kanagawa
TEL
045-787-2650
Homepage URL
Sponsor or person
Institute
Yokohama City University Department of Gastroenterological Surgery
Institute
Department
Personal name
Funding Source
Organization
Yokohama City University
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 03 | Month | 30 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2008 | Year | 08 | Month | 13 | Day |
Date of IRB
Anticipated trial start date
| 2008 | Year | 08 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2012 | Year | 03 | Month | 25 | Day |
Last modified on
| 2012 | Year | 03 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008634
